⁃ For Part A

• Body weight greater than or equal to (\>=) 45 kilograms (kg) and basal metabolic index (BMI) within the range 19.5 to 32 kilograms per square meters (kg/m\^2), inclusive

• Capable of giving signed informed consent,

• Participants who are overtly healthy as determined by medical evaluation by the investigator or a medically qualified designee based on medical history, physical examination, laboratory tests, and cardiac monitoring

• Women must be of non-childbearing potential

⁃ For Part B (planned Cohorts 1-3 and optional cohorts 4-5):

• Body weight \>=45 kg and BMI within the range 19.5 to 32 kg/m\^2, inclusive.

• Capable of giving signed informed consent, Confirmed diagnosis of Autosomal dominant polycystic kidney disease (ADPKD) by either applicable guidelines and/or genetic and imaging screening assessments

• Participants diagnosed with ADPKD may have complications or comorbidities directly related to ADPKD but should be otherwise healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests clinical testing

• Confirmation of known ADPKD causal genetic mutation(s) at the Polycystic kidney disease (PKD)1 and/or PKD2 loci based on genetic testing at screening and/or existing genetic information collected during the participant's routine clinical care for ADPKD from a genetic testing provider that, in the judgement of the investigator, is clinically valid.

• Mayo imaging classification groups 1C, 1D or 1E as assessed using the information collected at screening

• Estimated glomerular filtration rate (eGFR) greater than or equal to (\>=) 45 milliliters per minutes per 1.73 square meters (mL/min/1.73m\^2) (based on the Chronic kidney disease- Epidemiology Collaboration \[CKD-EPI 2021\] eGFR equation) and is not anticipated by the participant's regular treating physician to have a sustained decline by greater than (\>)10 percent (%) over the following 12 months

• Intolerant of tolvaptan treatment, unwilling to initiate tolvaptan treatment or ineligible for tolvaptan treatment for ADPKD

• A female participant is eligible to participate if she is not pregnant or breastfeeding and agrees to use birth control methods as discussed with the study doctor.

• Woman of childbearing potential (WOCBP) and Woman of non-childbearing potential (WONCBP) must have a negative highly sensitive pregnancy test prior to the Magnetic resonance imaging (MRI) scan being performed in the screening period of Part B

• A WOCBP and WONCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention For Part B (additional inclusion criteria for optional cohorts 4-5 only)

• eGFR \>=30 mL/min/1.73m\^2 (based on the CKD-EPI 2021 eGFR equation) and, in the clinical judgement of the investigator, the participant:

• has been clinically stable for the 24 months before screening; and,

• is not anticipated by the participant's regular treating physician to have a sustained decline in kidney function by \>10% over the following 12 months; and,

• is not anticipated to need renal replacement therapy in the next 12 months; and,

• does not have any other clinical, biochemical or familial feature at screening that suggests a clinically significant decline in kidney function is anticipated in the next 12 months.